
Bio-Techne Corp
TECH · NASDAQ · Healthcare / Biotechnology
Price History
Full chartMarket Stats
About
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Kim Kelderman
- Employees3.00K
- Headquarters614 McKinley Place N.E., Minneapolis, MN, United States, 55413, USA
- Websitehttps://www.bio-techne.com
Leadership
- Mr. Kim KeldermanCEO, President & Director · b. 1968
- Mr. James T. Hippel CPAExecutive VP of Finance & CFO · b. 1971
- Mr. Shane V. BohnenSenior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer · b. 1975
- Mr. William A. GeistPresident of Protein Sciences Segment · b. 1969
- Dr. Gary J. Latham Ph.D.VP & CTO
- Mr. David Clair C.F.A.Vice President of Investor Relations
- Mr. Martin WirtzSenior Vice President of Strategy & Corporate Development
- Ms. Cheryl BethuneSenior VP & Chief Human Resources Officer
- Mr. Luca CicchettiManaging Director
- Mr. Steven C. CrousePresident of Diagnostics & Spatial Biology Segment · b. 1973
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Analyst Ratings
- Strong Buy7
- Buy3
- Hold5
Ownership Breakdown
- Institutions
- 115.12%
- Insiders
- 0.33%
- Retail / Other
- 0.00%
Top Institutional Holders
- BlackRock Inc12.26M7.82%
- Vanguard Capital Management, LLC10.18M6.49%
- Morgan Stanley - Brokerage Accounts8.53M5.44%
- FMR Inc7.90M5.04%
- HBK INVESTMENTS L P6.83M4.35%
- Vanguard Portfolio Management, LLC6.48M4.13%
- State Street Corp5.87M3.74%
- Geode Capital Management, LLC5.11M3.26%
- Maverick Capital Ltd4.74M3.02%
- Amvescap Plc.4.59M2.93%
- Massachusetts Financial Services Company3.73M2.38%
- Ruane, Cunniff & Goldfarb L.P.3.35M2.14%
- Neuberger Berman Group LLC3.34M2.13%
- Snyder Capital Management LP3.16M2.02%
- UBS Group AG3.05M1.95%
- Mairs & Power Inc2.75M1.75%
Top Fund Holders
- Vanguard MStar Total Stk Mkt Idx Invest4.98M3.18%
- Vanguard 500 Index Investor4.16M2.65%
- Invesco S&P 500® Equal Weight ETF3.60M2.30%
- Vanguard Small Cap Index3.60M2.30%
Dividends
Stock Splits
- Nov 30, 20224:1
- Dec 4, 20002:1
- Nov 18, 19972:1